← 產業報告目錄
Biologics CDMO Market Size, Share & Trends Analysis Report By Cell Type (Mammalian, Non-mammalian), By Product Type (Biologics (Monoclonal Antibodies, Recombinant Proteins, Antisense and Molecular Therapy, Vaccines, Other Biologics, Biosimilars), By Region, And By Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-02頁數 180報告編號 INSIGHTACE-3b2fa4315f
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Valued at USD 24.2 Bn as of 2024, the global Biologics CDMO Market is expected to climb to USD 125.5 Bn by 2034, reflecting a compound annual growth rate of 18.1% over the 2025–2034 period.
The Biologics CDMO sector involves key industry insights & findings from the report:
the global biologics cdmo market is poised for a substantial growth, fueled by the expanding demand for biologics and biosimilars in the pharmaceut. This domain has witnessed substantial transformation owing to technological breakthroughs and shifting healthcare dynamics.
Market momentum is bolstered by expanding appetite for advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region expected to deliver the strongest growth trajectory through the forecast period, bolstered by demographic shifts and policy support.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Biologics CDMO Market Snapshot
Chapter 4. Global Biologics CDMO Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Cell Type Estimates & Trend Analysis
5.1. By Cell Type, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Cell Type:
5.2.1. Residential
5.2.2. Commercial
5.2.3. Industrial
5.2.4. Others
Chapter 6. Market Segmentation 2: By Product Type Estimates & Trend Analysis
6.1. By Product Type & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Product Type:
6.2.1. Biologics
6.2.1.1. Monoclonal Antibodies
6.2.1.2. Recombinant Proteins
6.2.1.3. Antisense and Molecular Therapy
6.2.1.4. Vaccines
6.2.1.5. Other Biologics
6.2.2. Biosimilars
Chapter 7. Biologics CDMO Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Biologics CDMO Market revenue (US$ Million) estimates and forecasts By Cell Type, 2021-2034
7.1.2. North America Biologics CDMO Market revenue (US$ Million) estimates and forecasts By Product Type, 2021-2034
7.1.3. North America Biologics CDMO Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Biologics CDMO Market revenue (US$ Million) estimates and forecasts By Cell Type, 2021-2034
7.2.2. Europe Biologics CDMO Market revenue (US$ Million) estimates and forecasts By Product Type, 2021-2034
7.2.3. Europe Biologics CDMO Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Biologics CDMO Market revenue (US$ Million) estimates and forecasts By Cell Type, 2021-2034
7.3.2. Asia Pacific Biologics CDMO Market revenue (US$ Million) estimates and forecasts By Product Type, 2021-2034
7.3.3. Asia Pacific Biologics CDMO Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Biologics CDMO Market revenue (US$ Million) estimates and forecasts By Cell Type, 2021-2034
7.4.2. Latin America Biologics CDMO Market revenue (US$ Million) estimates and forecasts By Product Type, 2021-2034
7.4.3. Latin America Biologics CDMO Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Biologics CDMO Market revenue (US$ Million) estimates and forecasts By Cell Type, 2021-2034
7.5.2. Middle East & Africa Biologics CDMO Market revenue (US$ Million) estimates and forecasts By Product Type, 2021-2034
7.5.3. Middle East & Africa Biologics CDMO Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Boehringer Ingelheim Group
8.2.2. Lonza Group
8.2.3. Samsung Biologics
8.2.4. NOVARTIS AG
8.2.5. Toyobo Co. Limited
8.2.6. Parexel International Corporation
8.2.7. Catalent Inc.
8.2.8. Binex Co. Limited
8.2.9. AGC Biologics
8.2.10. AbbVie Contract Manufacturing
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們